Trastuzumab with chemo for HER2-positive breast cancer
Part of Cancer clinical trials.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 to 70
- Your invasive breast cancer is confirmed as HER2-positive (IHC +++ or FISH amplification)
- Your hormone status (ER and PR) is known
- Your cancer is either operable/locally advanced/inflammatory and you have not had prior anti-cancer treatment for the breast cancer
- Your heart pumping function is strong (left ventricular ejection fraction at least 55%)
- Your blood counts and organs (kidney, liver, bone marrow) are in an acceptable range for treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) as maintenance therapy to keep HER2-positive breast cancer that has spread under control. It is for women who have already received some first-line treatment and are stable enough to continue therapy.
This trial tests a treatment for early-stage HER2-positive breast cancer that is small and has not spread to lymph nodes. It aims to reduce the chance of cancer returning after surgery.
This trial tests a new antibody-drug combination (trastuzumab rezetecan, also called T-DXd) for patients with HER2-positive breast cancer whose tumor did not fully disappear after initial chemotherapy. The goal is to see if this drug can reduce the risk of cancer coming back.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.